Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Refractory/Relapse Neuroblastoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neuroendocrine Tumors 1 Neoplasms, Squamous Cell 1 Neoplasms 1 Nasopharyngeal Carcinoma 1 Lymphoma 1 Lung Neoplasms 1 Hysterectomies for Low- or Intermediate-risk Endometrial Carcinoma 1 Esophageal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

lutetium Lu 177 dotatate 21 Magnetic Resonance Spectroscopy 10 pembrolizumab 9 Specimen Handling 7 Everolimus 7 cabozantinib 6 Nivolumab 6 lenvatinib 5 Capecitabine 5 177Lu-octreotide, DOTA(0)-Tyr(3)- 5 surufatinib 4 olaparib 4 amino-acid, glucose, and electrolyte solution 4 lanreotide 3 atezolizumab 3 Temozolomide 3 Octreotide 3 Lutetium-177 3 Ipilimumab 3 Injections 3 Fluorodeoxyglucose F18 3 Cyclophosphamide 3 gallium Ga 68 dotatate 2 fludarabine phosphate 2 fludarabine 2 avelumab 2 X-Rays 2 Radiotherapy 2 Phantoms, Imaging 2 PM 01183 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neuroendocrine Tumors × Biological Products × 1 year × Clear all

NCT07366658 2026-01-26

NEUK203-13

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 1 Not yet recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡